A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
View/ Open
Date
2016-11-01Author
Jamieson, D
Griffin, MJ
Sludden, J
Drew, Y
Cresti, N
Swales, K
Merriman, M
Allen, R
Bevan, P
Buerkle, M
Mala, C
Coyle, V
Rodgers, L
Dean, E
Greystoke, A
Banerji, U
Wilson, RH
Evans, TRJ
Anthoney, A
Ranson, M
Boddy, AV
Plummer, R
Type
Journal Article
Metadata
Show full item recordAbstract
PURPOSE: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determine the optimal biological dose for subsequent trials. EXPERIMENTAL DESIGN: Patients with treatment-refractory, advanced solid tumours, with adequate performance status and organ function were recruited to a dose-escalation study in a standard 3 + 3 design. The starting dose was 25 mg orally once weekly with toxicity, PK and PD guided dose-escalation with potential to explore alternative schedules. RESULTS: Forty-one patients with advanced solid tumours refractory to standard therapies and with adequate organ function were recruited in eight cohorts up to doses of 150 mg once weekly and 75 mg twice weekly. No dose-limiting toxicities were observed during the study, and a maximum tolerated dose (MTD) was not established. The highest dose cohorts demonstrated sustained inhibition of extracellular signal-regulated kinase (ERK) phosphorylation in peripheral blood mononuclear cells following ex-vivo phorbol 12-myristate 13-acetate stimulation. There was a decrease of 70 ± 26% in mean phosphorylated (p)ERK in C1 day 8 tumour biopsies when compared with pre-treatment tumour levels in the 75 mg twice a week cohort. Prolonged stable disease (>6 months) was seen in two patients, one with cervical cancer and one with ampullary carcinoma. CONCLUSIONS: WX-554 was well tolerated, and an optimal biological dose was established for further investigation in either a once or twice weekly regimens. The recommended phase 2 dose is 75 mg twice weekly.
Collections
Subject
Humans
Neoplasms
Mesothelioma
Cholangiocarcinoma
Carcinoma, Non-Small-Cell Lung
Bile Duct Neoplasms
Esophageal Neoplasms
Colorectal Neoplasms
Pancreatic Neoplasms
Lung Neoplasms
Drug Eruptions
Fatigue
Abdominal Pain
Anorexia
Diarrhea
Nausea
MAP Kinase Kinase 1
MAP Kinase Kinase 2
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
Ribosomal Protein S6 Kinases, 70-kDa
Phosphoproteins
Protein Kinase Inhibitors
Chromatography, Liquid
Chromatography, High Pressure Liquid
Administration, Oral
Maximum Tolerated Dose
Allosteric Regulation
Adult
Aged
Middle Aged
Uterine Cervical Neoplasms
Female
Male
Proto-Oncogene Proteins c-akt
Tandem Mass Spectrometry
Glycogen Synthase Kinase 3 beta
Research team
Clinical PD Biomarker Group
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Language
eng
Date accepted
2016-08-27
License start date
2016-11
Citation
European journal of cancer (Oxford, England : 1990), 2016, 68 pp. 1 - 10
Publisher
ELSEVIER SCI LTD
Related items
Showing items related by title, author, creator and subject.
-
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker, SR; Cowley, GS; Wagner, S; Luo, F; Root, DE; et al. (AMER ASSOC CANCER RESEARCH, 2015-12-01)RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant colorectal cancer. To gain additional insights into this difference, we performed a genome-scale pooled shRNA enhancer screen in a ... -
PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.
Gupta, A; Anjomani-Virmouni, S; Koundouros, N; Dimitriadi, M; Choo-Wing, R; et al. (CELL PRESS, 2017-03-16)PARK2 is a gene implicated in disease states with opposing responses in cell fate determination, yet its contribution in pro-survival signaling is largely unknown. Here we show that PARK2 is altered in over a third of all ... -
TGFβ-mediated suppression of CD248 in non-cancer cells via canonical Smad-dependent signaling pathways is uncoupled in cancer cells.
Suresh Babu, S; Valdez, Y; Xu, A; O'Byrne, AM; Calvo, F; et al. (2014-02-20)Background CD248 is a cell surface glycoprotein, highly expressed by stromal cells and fibroblasts of tumors and inflammatory lesions, but virtually undetectable in healthy adult tissues. CD248 promotes tumorigenesis, while ...